Hatice Satilmis
Overview
Explore the profile of Hatice Satilmis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verheye E, Kancheva D, Satilmis H, Vandewalle N, Fan R, Bardet P, et al.
J Hematol Oncol
. 2024 Nov;
17(1):107.
PMID: 39511632
Background: The long-term effectiveness of immunotherapies against Multiple Myeloma (MM) remains elusive, demonstrated by the inevitable relapse in patients. This underscores the urgent need for an in-depth analysis of the...
2.
Vandewalle N, Satilmis H, Verheye E, Fan R, Wang Y, De Groof T, et al.
Theranostics
. 2024 May;
14(7):2656-2674.
PMID: 38773967
AXL expression has been identified as a prognostic factor in acute myeloid leukemia (AML) and is detectable in approximately 50% of AML patients. In this study, we developed AXL-specific single...
3.
Fan R, Satilmis H, Vandewalle N, Verheye E, de Bruyne E, Menu E, et al.
Blood Cancer J
. 2023 Dec;
13(1):188.
PMID: 38110349
Acute Myeloid Leukemia (AML) is a heterogeneous disease with limited treatment options and a high demand for novel targeted therapies. Since myeloid-related protein S100A9 is abundantly expressed in AML, we...
4.
Van der Vreken A, Oudaert I, Ates G, Faict S, Vlummens P, Satilmis H, et al.
J Pathol
. 2023 Feb;
260(2):112-123.
PMID: 36807305
Multiple myeloma (MM) remains an incurable haematological malignancy despite substantial advances in therapy. Hypoxic bone marrow induces metabolic rewiring in MM cells contributing to survival and drug resistance. Therefore, targeting...
5.
Fan R, Satilmis H, Vandewalle N, Verheye E, Vlummens P, Maes A, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36650020
Background: Immunotherapy emerged as a promising treatment option for multiple myeloma (MM) patients. However, therapeutic efficacy can be hampered by the presence of an immunosuppressive bone marrow microenvironment including myeloid...
6.
Satilmis H, Verheye E, Vlummens P, Oudaert I, Vandewalle N, Fan R, et al.
J Pathol
. 2022 Oct;
259(1):69-80.
PMID: 36245401
While multi-drug combinations and continuous treatment have become standard for multiple myeloma, the disease remains incurable. Repurposing drugs that are currently used for other indications could provide a novel approach...
7.
Oudaert I, Satilmis H, Vlummens P, De Brouwer W, Maes A, Hose D, et al.
J Exp Clin Cancer Res
. 2022 Feb;
41(1):45.
PMID: 35105345
Background: Multiple myeloma (MM) remains an incurable cancer despite advances in therapy. Therefore, the search for new targets is still essential to uncover potential treatment strategies. Metabolic changes, induced by...